Biocon expects stronger H2 driven by US biosimilar launches

Biocon is a company that makes medicines.

Some of its medicines are copies of other popular medicines, called biosimilars.

These biosimilar copies usually cost less than the original.

Biocon has started selling several of these new medicines in the United States.

The company says sales will be much better in the second half of the year.

In the first three months, Biocon's money made from sales went up by 10 per cent.

One new eye medicine, called Yesafili, could sell in a market worth about $3 billion.

The US rules have changed so it is easier for companies that are good at making biosimilars.

This helps Biocon and other experienced companies.

Biocon says it will keep spending about 7 per cent of its revenue on research and development.